| Liebowitz, Michael |
NCT05384483: Cariprazine Versus Placebo for Social Anxiety Disorder |
|
|
| Completed | 4 | 40 | US | Cariprazine, Vraylar®, Placebo | The Medical Research Network, AbbVie | Social Anxiety Disorder | 04/24 | 04/24 | | |
| Terminated | 3 | 324 | US | PH94B Nasal Spray, Placebo Nasal Spray | VistaGen Therapeutics, Inc. | Social Anxiety Disorder | 08/22 | 08/22 | | |
PALISADE-3, NCT06358651: Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults with Social Anxiety Disorder |
|
|
| Recruiting | 3 | 236 | US | Fasedienol Nasal Spray, Placebo Nasal Spray | VistaGen Therapeutics, Inc. | Social Anxiety Disorder | 06/25 | 06/26 | | |
| Completed | 2 | 210 | Europe, US, RoW | vafidemstat, ORY-2001, Placebo | Oryzon Genomics S.A. | Borderline Personality Disorder | 10/23 | 11/23 | | |
| Schneider, Stephen |
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 255 | US | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 02/25 | 02/26 | | |
| Recruiting | 3 | 200 | US | Placebo, MM120 (LSD D-Tartrate) | Mind Medicine, Inc. | Generalized Anxiety Disorder | 05/26 | 11/26 | | |
| Active, not recruiting | 2/3 | 256 | US | BHV-7000, Placebo | Biohaven Therapeutics Ltd. | Bipolar Disorder | 03/25 | 04/25 | | |
NCT05407064: A Dose-Finding Study of MM-120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms |
|
|
| Completed | 2 | 198 | US | MM-120 (LSD D-Tartrate), Placebo | Mind Medicine, Inc. | Anxiety Generalized | 10/23 | 11/23 | | |
| Recruiting | 2 | 60 | Europe, US, RoW | Methylone | Transcend Therapeutics | Post Traumatic Stress Disorder | 12/25 | 12/25 | | |
NCT06419608: Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression |
|
|
| Recruiting | 2 | 300 | US | BHV-7000, Placebo | Biohaven Therapeutics Ltd. | Major Depressive Disorder | 05/25 | 07/25 | | |
| Gruener, Daniel |
| Active, not recruiting | 2/3 | 256 | US | BHV-7000, Placebo | Biohaven Therapeutics Ltd. | Bipolar Disorder | 03/25 | 04/25 | | |
NCT06419608: Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression |
|
|
| Recruiting | 2 | 300 | US | BHV-7000, Placebo | Biohaven Therapeutics Ltd. | Major Depressive Disorder | 05/25 | 07/25 | | |
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder |
|
|
| Recruiting | 2 | 300 | US | INDV-2000, Placebo | Indivior Inc. | Opioid Use Disorder | 08/25 | 09/25 | | |
| Recruiting | 2 | 122 | US | INDV-6001, Suboxone, Sublocade | Indivior Inc. | Moderate to Severe Opioid Use Disorder | 10/25 | 10/25 | | |
| Banov, Michael |
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 255 | US | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 02/25 | 02/26 | | |
NCT05169710 / 2021-002126-24: A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder. |
|
|
| Terminated | 3 | 83 | Europe, Canada, Japan, US | SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo | Sumitomo Pharma America, Inc., Sunovion Pharmaceuticals Inc. | Depressive Episodes, Bipolar I Depression | 10/23 | 10/23 | | |
ENLIGHTEN, NCT05113771: A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression |
|
|
| Completed | 2 | 197 | Canada, US | Liafensine, Placebo | Denovo Biopharma LLC | Treatment Resistant Depression | 02/24 | 03/24 | | |
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression |
|
|
| Recruiting | N/A | 6800 | US | Vagus Nerve Stimulation (VNS), VNS | LivaNova | Treatment Resistant Depression | 02/28 | 12/30 | | |
| Nadjafi, Morteza |
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 255 | US | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 02/25 | 02/26 | | |
EBS-101-TD-391, NCT06021522: A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder |
|
|
| Recruiting | 3 | 150 | Europe, Canada, US, RoW | Ecopipam, Ecopipam Hydrochloride | Emalex Biosciences Inc. | Tourette Syndrome | 11/24 | 03/27 | | |
| Active, not recruiting | 3 | 196 | Europe, Canada, US, RoW | Ecopipam Hydrochloride | Emalex Biosciences Inc. | Tourette Disorder | 12/24 | 12/24 | | |
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 568 | Europe, Canada, US, RoW | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 03/25 | 05/25 | | |
NCT05081245: ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) |
|
|
| Recruiting | 2 | 150 | Canada, US, RoW | ML-004 (IR)/(ER) tablet, ML-004 Placebo | MapLight Therapeutics | Autism Spectrum Disorder | 03/25 | 04/25 | | |
UNCOVER, NCT04753385: The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes |
|
|
| Terminated | N/A | 138 | US | | LivaNova | Treatment Resistant Depression | 09/24 | 09/24 | | |
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression |
|
|
| Recruiting | N/A | 6800 | US | Vagus Nerve Stimulation (VNS), VNS | LivaNova | Treatment Resistant Depression | 02/28 | 12/30 | | |
| Figueroa, Colleen |
| Completed | 4 | 246 | US | Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH), placebo | Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac | Attention Deficit/Hyperactivity Disorder | 05/24 | 05/24 | | |
| Active, not recruiting | 4 | 123 | US | Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) | Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac, Worldwide Clinical Trials | Attention Deficit/Hyperactivity Disorder | 07/25 | 07/25 | | |
NCT04641143: Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder |
|
|
| Recruiting | 3 | 700 | US | Troriluzole, Placebo | Biohaven Pharmaceuticals, Inc. | Obsessive-Compulsive Disorder | 06/25 | 06/25 | | |
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 255 | US | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 02/25 | 02/26 | | |
| Recruiting | 2/3 | 160 | US | NRCT-101SR, Matching Placebo | Neurocentria, Inc. | Attention-Deficit/Hyperactivity Disorder (ADHD) | 12/24 | 02/25 | | |
| Wagner, Louis |
| Active, not recruiting | 2/3 | 256 | US | BHV-7000, Placebo | Biohaven Therapeutics Ltd. | Bipolar Disorder | 03/25 | 04/25 | | |
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia |
|
|
| Active, not recruiting | 2 | 350 | US | LB-102 | LB Pharmaceuticals Inc. | Schizophrenia | 12/24 | 05/25 | | |
NCT06419608: Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression |
|
|
| Recruiting | 2 | 300 | US | BHV-7000, Placebo | Biohaven Therapeutics Ltd. | Major Depressive Disorder | 05/25 | 07/25 | | |
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder |
|
|
| Recruiting | 2 | 300 | US | INDV-2000, Placebo | Indivior Inc. | Opioid Use Disorder | 08/25 | 09/25 | | |
| Suplicy, Felipe |
| Active, not recruiting | 4 | 123 | US | Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) | Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac, Worldwide Clinical Trials | Attention Deficit/Hyperactivity Disorder | 07/25 | 07/25 | | |
NCT06389487: A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above |
|
|
| Active, not recruiting | 3 | 1458 | Europe, Canada, Japan, US, RoW | RSVPreF3 OA investigational vaccine | GlaxoSmithKline | Respiratory Syncytial Virus Infections | 07/24 | 04/25 | | |
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 255 | US | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 02/25 | 02/26 | | |
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 568 | Europe, Canada, US, RoW | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 03/25 | 05/25 | | |
| Recruiting | 2/3 | 560 | US | IHL-42X Low Dose, Phase 2 Investigational Product - IHL-42X Low dose, IHL-42X High Dose, Phase 2 Investigational Product - IHL-42X High dose, Placebo, Phase 2 Placebo, IHL-42X (Optimal Dose), Phase 3 Investigational Product - IHL-42X, Dronabinol, Phase 3 Comparator - Reference Listed Drug/Dronabinol, Acetazolamide, Phase 3 Comparator - Reference Listed Drug/Acetazolamide, Phase 3 Placebo | Incannex Healthcare Ltd | Obstructive Sleep Apnea | 12/26 | 12/26 | | |
NCT06702449: A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age |
|
|
| Recruiting | 1/2 | 448 | Europe, US, RoW | Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1, Candidate UTI vaccine medium dose formulation 2, Candidate UTI vaccine high dose formulation 1, Candidate UTI vaccine high dose formulation 2, Candidate UTI vaccine HTD formulation 2, Placebo | GlaxoSmithKline | Urinary Tract Infections | 08/27 | 08/27 | | |
| Kitwood, Schiara |
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 255 | US | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 02/25 | 02/26 | | |
| Kane, Jennifer |
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 255 | US | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 02/25 | 02/26 | | |
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression |
|
|
| Recruiting | N/A | 6800 | US | Vagus Nerve Stimulation (VNS), VNS | LivaNova | Treatment Resistant Depression | 02/28 | 12/30 | | |
| Turzilli, Matt T |
NCT05384483: Cariprazine Versus Placebo for Social Anxiety Disorder |
|
|
| Completed | 4 | 40 | US | Cariprazine, Vraylar®, Placebo | The Medical Research Network, AbbVie | Social Anxiety Disorder | 04/24 | 04/24 | | |
NCT06419608: Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression |
|
|
| Recruiting | 2 | 300 | US | BHV-7000, Placebo | Biohaven Therapeutics Ltd. | Major Depressive Disorder | 05/25 | 07/25 | | |
| Careri, Jason |
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 255 | US | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 02/25 | 02/26 | | |
NCT05729373: A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder |
|
|
| Recruiting | 2/3 | 434 | Europe, Japan, US | SEP-363856, Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Generalized Anxiety Disorder | 02/26 | 02/26 | | |
| Scull, Skylar |
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 255 | US | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 02/25 | 02/26 | | |
| Tumarkin, Nancy Bloss |
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 255 | US | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 02/25 | 02/26 | | |
| Negrón-Muñoz, Rosa |
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 255 | US | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 02/25 | 02/26 | | |
